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Abstract
Ribonucleic acids (RNAs) are considered as effective and minimally invasive biomarkers for disease
diagnosis and prognosis due to their critical role in the regulation of different cellular processes. Over the
past several years, the rapid progress in RNA biomarker research has resulted in the development of a
large number of high-performance RNA-detection methods. Most of these methods are based on
molecular-biology techniques such as quantita-tive reverse transcription polymerase chain reaction (RTqPCR), microarrays, and RNA sequencing. In recent years, considerable attention has also been dedicated
to developing RNA biosensors, exploiting micro- and nanofabrica-tion technologies, and various readout
strategies, including electrochemical and optical transducers. Here, the recent developments of RNA
biosensors are concisely reviewed with a special emphasis on electrochemical-detection approaches.
The following points are also highlighted: i) all the types of clini-cally relevant RNAs (mRNAs, miRNAs,
lncRNAs) and their diagnostic and prognostic potential in cancer are outlined, ii) major challenges
associated with current techniques are identified, followed by a critical analysis of how these challenges
have been addressed by different biosensing approaches, and iii) the current requirements that still need
to be met for effective screening of RNA biomarkers in both research and clinical settings.
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Ribonucleic acids (RNAs) are considered as effective and minimally invasive
biomarkers for disease diagnosis and prognosis due to their critical role in
the regulation of different cellular processes. Over the past several years, the
rapid progress in RNA biomarker research has resulted in the development
of a large number of high-performance RNA-detection methods. Most of
these methods are based on molecular-biology techniques such as quantitative reverse transcription polymerase chain reaction (RT-qPCR), microarrays,
and RNA sequencing. In recent years, considerable attention has also been
dedicated to developing RNA biosensors, exploiting micro- and nanofabrication technologies, and various readout strategies, including electrochemical
and optical transducers. Here, the recent developments of RNA biosensors
are concisely reviewed with a special emphasis on electrochemical-detection
approaches. The following points are also highlighted: i) all the types of clinically relevant RNAs (mRNAs, miRNAs, lncRNAs) and their diagnostic and
prognostic potential in cancer are outlined, ii) major challenges associated
with current techniques are identified, followed by a critical analysis of how
these challenges have been addressed by different biosensing approaches,
and iii) the current requirements that still need to be met for effective
screening of RNA biomarkers in both research and clinical settings.
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1. Introduction

Ribonucleic acid (RNA) biomarkers comprising different coding and noncoding
transcriptome such as messenger RNA
(mRNA), microRNA (miRNA), and long
noncoding RNA (lncRNA) are becoming
progressively crucial in understanding
disease diagnosis and prognosis due to
their recognized physiological role in gene
expression and regulation.[1–9] Dysregulation of these RNA biomarkers is involved
in the initiation and progression of several
diseases including cancers.[2,10–15] Among
the different types of RNAs, proteincoding RNAs are exclusively represented
by mRNAs where aberrant mRNA expression could initiate cancer by altering the
DNA methylation pattern and different
cellular regulatory pathways such as chromatin modifications, cell adhesion, and
cell cycles.[5,8] A number of recent studies
have reported a strong correlation between
aberrantly expressed mRNA levels and
various cancers including breast cancer,[16]
[17]
lung cancer,
malignant melanoma,[18] and hepatocellular
[19]
carcinoma.
During mRNA biogenesis (i.e., transcription),
mature mRNA is produced from pre-mRNA transcripts via a
splicing process (i.e., introns removal from nascent RNA followed by the joining of exons).[20,21] Any alterations in this
splicing pattern, referred to as “alternative splicing”, may
trigger the production of miscellaneous mRNA isomers, which
further generates diverse protein variants including oncoproteins.[2,21,22] For example, alternatively spliced Fas mRNA
isoform (exon 6 is missing) produces a soluble deregulatory
protein known as sFas which triggers abnormal cell proliferation in cancer.[2,23]
These protein-coding mRNA genes represent only a
small percentage of the total genome. On the contrary, more
than 90% of the genomic DNA generates noncoding RNAs
(ncRNAs), consisting of housekeeping (e.g., ribosomal RNA,
transfer RNA) and regulatory noncoding RNAs (e.g., miRNA
and lncRNA).[24] In recent years, research focus has mostly been
shifted toward discovery and translational studies of biomarkers
based on miRNAs (19–25 bases) and lncRNAs (200 bases to
100 kilobases), due to their strong ability in regulating the gene
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expression.[4,10,25] These RNAs do not take part in protein production (i.e., translation) but they actively regulate the post-transcriptional gene expression and remodeling of the epigenome
(i.e., DNA methylation and histone modification).[26,27] They
are crucial for a range of controlled biological processes such
as cell cycle regulation, pluripotency, retrotransposon silencing,
etc. These controlled processes may be affected and eventually
could contribute to cancer development when the sequences of
noncoding RNAs have anomalies such as copy number variations, single nucleotide polymorphism, and mutations.[3,14] For
instance, it has been reported that dysregulated lncRNA, HOX
transcript antisense RNA (HOTAIR), interacted with polycomb
repressive complex 2 (PRC2) complex and actively involved in
the progression of liver and breast cancer,[25] whereas MALAT1
B7 lncRNA affected the RNA splicing functions and triggered
several types of cancers such as breast, lung, uterus, pancreas,
colon, prostate, and liver cancer.[25,28–30]
Until now, nucleic-acid-detection-based techniques such
as quantitative reverse transcription polymerase chain reaction (RT-qPCR),[31,32] microarrays,[33,34] and RNA sequencing
methods,[4,35] have widely been applied for the effective analysis
of RNA levels. These methods typically require some forms of
amplification steps, cumbersome sample pretreatment procedure, and expensive instrumentation. Additionally, they often
cannot amplify RNA sequences without a poly(A) tail due to
the use of oligo(dT) primers for the amplification purpose.[36]
Additionally, relatively large sample volumes are required for
sensing RNA biomarkers in body fluids to avoid sample heterogeneity, resulting from distinct physiological and systemic
differences of clinical samples.[37] In this regard, a great deal of
research has been carried out to find relatively robust, accurate,
and effective methods, leading to several nanotechnology-based
RNA sensing approaches coupled with optical and electrochemical readouts. These approaches offer relatively easy sampling procedures, rapid and cost-effective analysis, portability,
label-free and amplification-free options.[38–42] Among these
methods, electrochemical methods have evidently achieved the
ultrahigh sensitivity and selectivity with the high potential for
multiplexed analysis in point-of-care platform.[40,43,44] However,
the functionality of electrochemical RNA sensors is still confined in the proof-of-concept studies and several challenges are
yet to be addressed to transform the technologies into routine
clinical applications.[37]
Here, we review the recent developments of RNA biosensing approaches, especially electrochemical approaches.
The diagnostic and prognostic roles of RNA biomarkers are
briefly discussed, followed by a specific discussion on current
requirements that still need to be met for screening of RNA
biomarkers in both research and clinical settings. We have
also highlighted the major technical and biological challenges
involved in the existing RNA detection strategies and provided
suggestions for the future direction of the field.

2. RNA Biogenesis
The rate and extent of RNA biogenesis in the nucleus and their
subsequent role in protein synthesis or gene regulation are subjected to several finely controlled pathways driven by various
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Figure 1. Schematic overview of miRNA biogenesis and regulation pathways. In the nucleus, miRNA genes are first transcribed to hairpin-structured
pri-miRNA by RNA Pol. Next, microprocessor complex (Drosha and DGCR8) cleaves pri-miRNA to produce pre-miRNA, which is exported to the cytoplasm. In the cytoplasm, further cleavage by Dicer results in the formation of miRNA duplexes. Following strand separation of the duplexes, the mature
miRNAs accumulate into RISCs to exert the regulatory function. Reproduced with permission.[37] Copyright 2015, John Wiley and Sons.

cellular factors and enzymes.[45–47] mRNA is synthesized in the
nucleus from the DNA template of a target gene via a process
known as “transcription.” The transcription process is catalyzed
by a large molecular enzyme referred to as RNA polymerase II
(RNA Pol II). RNA Pol II recognizes and binds to the promoter
site of the template DNA with the help of a group of proteins
known as general transcription factors (GTFs).[48] First, GTFs
(e.g., TFIIA, TFIIB, TFIID, TFIIE, TFIIF, and TFIIH) assemble
near the template DNA and assist RNA Pol II to recognize
and bind the specific promoter region of the DNA thereby
forming the preinitiation complex (PIC). The PIC then recruits
DNA helicases, which facilitate DNA to expose their template
strand for the initiation of RNA synthesis. After the initiation
of transcription, the PIC leaves the template strand and RNA
Pol II starts the elongation process and transcribes hundreds
of kilobases of pre-mRNA transcripts. After that the RNA Pol
II is dissociated from DNA template and started re-initiation
of downstream transcription pathways.[45,46,49] The resultant
nascent pre-mRNA undertakes three major processing steps to
form mature mRNAs, which usually occur co-transcriptionally
(i.e., transcription and pre-mRNA processing happens simultaneously). These steps are 5′ capping, splicing and 3′ adenylation.[45,50] Upon completion of the processing steps, mature
mRNA is packaged inside a complex consisted of RNA binding
proteins and other export factors.[45] Then this complex is transported from the nucleus to cytoplasm through the nuclear pore
complex which spans over the nuclear envelope (NPC) for further activities.[45]
Similarly, miRNAs are synthesized in the nucleus by the
same transcriptional machinery of mRNA biogenesis.[51] However, after their export into the cytoplasm, they skip the protein
synthesis steps and keep a role in gene regulation.[37,52] During
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miRNA biogenesis (Figure 1), miRNA genes are first converted
to hairpin-structured primary miRNA (pri-miRNA) by either
RNA pol I or II via transcription process. Pri-miRNAs are then
cleaved and processed by a distinct protein complex known as
the microprocessor complex, which consists of ribonuclease
enzyme Drosha and RNA binding protein DGCR8 (also known
as pasha). In the next step, the miRNAs are then exported to the
cytoplasm and further cleaved by Dicer (an enzyme from RNase
III family) to form miRNA duplexes. Following strand separation of the duplexes, mature miRNAs are produced, which start
to accumulate various proteins and enzymes to form RNAinduced silencing complex (RISC). miRNA exerts its inhibitory
and regulatory action via RISC-induced RNA degradation and
post-translational inhibition.[52] Although many aspects of the
lncRNA biogenesis pathways are relatively less understood, it
has been reported that the key processes involved in most of
the recently discovered lncRNAs follow the common mRNA
biogenesis pathway.[51,53] However, a few other alternative pathways for the biogenesis of lncRNAs have been described, which
employ another type of polymerase enzyme known as RNA pol
III at the gene promoters and do not undergo a polyadenylation
processing step.[51,54]

3. Diagnostic and Prognostic Roles of RNA
RNAs are the key regulators of gene expression network and
involved in controlling cell-cycle, cell proliferation, differentiation, apoptosis, metabolism, and post-transcriptional pathways.[2–6,8] Dysregulated RNAs can affect one or several of
these cellular pathways, resulting in tumor initiation and progression. Thus, they can be used in diagnosis, prognosis, and
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therapy monitoring of cancers.[5,55,56] Although the specificity
and reproducibility of circulating miRNA biomarkers is a subject to recent contradictory discussion (see Section 3.3), they
offer several distinct advantages such as early detection, high
stability, and ability to work as liquid biopsy for minimally invasive monitoring of cancer.
Early Detection: A number of studies have confirmed that
RNA biomarkers have important clinical implications as the
early indicator of cancer.[17,18,57–62] This is mostly due to the fact
that during the early development of tumor cells, they release
significant amounts of RNA into the blood circulation and
mostly being upregulated. For example, miR-200 was reported
as an effective biomarker for the early detection of ovarian
cancer.[63]
High Stability of Circulating miRNAs: Compared to mRNAs
and lncRNAs, miRNAs have significantly higher stability in a
clinical sample and can show robust expression pattern.[3,37,55,62]
Several studies have shown that circulating miRNAs are
resistant to the degradation by RNases and also unaffected in
extreme condition such as freeze–thawing, long-term storage,
high pH, and temperature. This high stability can be explained
by the fact that they are well protected inside the microvesicles
such as exosomes and apoptotic bodies, or attached with RNAbinding proteins.[63–65]
Circulating Biomarker for Minimally Invasive Detection of
Cancers: Current techniques for cancer diagnosis commonly
require invasive tissue biopsy, which is not always clinically
feasible and associated with pain.[66] However, tumor-specific
circulating RNAs (miRNAs) available in accessible biological
fluids such as serum, plasma, urine, saliva could bypass the
need of tissue biopsy.[3,57,67,68] In 2010, Weber et al.[69] assessed
12 different body fluids including urine, saliva, plasma, tears,
breast milk, peritoneal fluid, pleural fluid, seminal fluid, amniotic fluid, bronchial lavage, cerebrospinal fluid, and colostrum
and showed that miRNAs are present in these body fluids. This
wide distribution of miRNA in most biological fluids makes
them a promising circulating biomarker for less or noninvasive
diagnosis and more personalized monitoring of diseases.[66]
The prominent features of using miRNAs as a circulating biomarker are that they are minimally painful, and allow clinicians
to quickly assess disease development and response to therapeutics.[70] For example, Debernardi et al.[71] showed a noninvasive profiling of cell-free miRNAs extracted from the urine
of patients with pancreatic ductal adenocarcinoma and chronic
pancreatitis can efficiently differentiate the early and late stage
tumors.

3.1. Diagnostic Roles
Different types of cancers have distinctive signature of mRNA
expression pattern. For example, Miura et al.[17] demonstrated
that the expression of human telomerase reverse transcriptase
(hTERT) mRNA and epidermal growth factor receptor (EGFR)
mRNA were associated with lung cancer metastasis. In this
study, real-time RT-PCR was used to measure the serum
hTERT mRNA and EGFR mRNA levels from 112 patients
with lung cancer and 80 normal individuals. The levels of
the mRNAs were significantly interrelated with tumor size,
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number, metastasis, and recurrence in lung cancer which
elucidated hTERT and EGFR mRNA’s role as diagnostic biomarker for lung cancer. Several other mRNAs were reported
as the diagnostic indicators of epithelial ovarian cancer (EOC)
due to their specific expression patterns in EOC. For instance,
p53, BCL-2, BAX mRNAs are downregulated in EOC while
ASAP1 mRNA is overexpressed.[72,73] A genome wide analyses
of mRNA expression in 136 breast cancer patients performed
via RNA sequencing (RNA-seq) also showed that a number of
32 mRNAs can sensitively act as the diagnostic biomarkers for
breast cancer.[74]
Alternative splicing can also trigger the production of aberrant mRNA isomers leading to the progression of many diseases
including cancer.[21] This could happen due to the mutations in
the components of splicing machineries.[11] A number of tumorspecific alternative splicing events have been reportedly considered as the effective diagnostic markers and therapeutic targets
in different cancers such as breast and lung cancer.[75,76] Additionally, mRNA fusion, which is usually generated from gene
fusion during aberrant chromosomal rearrangement events,
have emerged as the new class of sensitive and specific diagnostic biomarkers for many cancers. For instance, TMPRSS2ERG and BCR-ABL mRNA fusions have been used as diagnostic
markers for prostate cancer[59] and leukemia,[77] respectively.
In recent years, much attention has been dedicated to
explore the diagnostic significance of miRNAs in cancer.[3,10,78]
In 2002, Calin et al.[79] drew a relationship between cancer- and
tissue-derived miRNA where it was demonstrated that miRNA
cluster miR 15/16 was downexpressed in chronic lymphocytic
leukemia. In a large cohort study, Volinia et al.[80] screened
540 tumor samples derived from lung, breast, stomach, prostate, colon, and pancreas cancers, and identified 43 dysregulated miRNAs as diagnostic biomarkers. Later, in 2008, the
diagnostic role of circulating miRNA in B-cell lymphoma was
reported by Lawrie et al.[81] This study reported that the levels
of miR-21 and miR-155 were significantly higher in the serum
sample derived from cancer patients compared to that of normal
sample. Since then, an increasing number of cancer-related circulating miRNA have been identified and studied.[3,10,82] For
example, Zhou et al.[82] showed the positive diagnostic potential
of a group of circulating miRNAs (miR-122, miR-192, miR-21,
miR-223, miR-26a, miR-27a, and miR-801) in a hepatocellular
carcinoma (HCC) patient sample. In recent times, there is also
an increasing interest on lncRNAs’ research due to their wide
biological functions and diagnostic potential.[12,25,60,83] Among
different lncRNAs, dysregulated HOTAIR is of great interest
due to their robust expression pattern and active involvement
in the prognosis, metastasis, and recurrence of a range of cancers.[13,25,60,83,84] For example, Gupta et al.[84] showed that the
rate of HOTAIR transcription in metastatic breast cancer was
almost 2000-fold raised compared to that of control. This significantly elevated levels of HOTAIR in cancer cells demonstrates
their high diagnostic potential.

3.2. Prognostic Roles
Aberrant mRNAs have also been considered as a good indicator
to predict and track tumor prognosis. In 2004, Spentzos et al.[85]
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showed the positive prognostic behavior of a number of 115
mRNAs present in 68 patients with ovarian cancers where
the mRNA profiling data successfully could predict the survival rate of patients. In another genome-wide approach, De
Sousa et al.[86] recruited 1100 patients with colorectal cancer
where mRNA biomarkers successfully commented on the prognosis of colorectal cancer. In a few other related studies, aberrantly expressed NOTCH1 mRNA was found to be interrelated
with poor survival of patients with non-Hodgkin lymphoma[87]
while Cyclin D1 and TS mRNA was linked with the poor survival of breast cancer patients.[16]
Compared to mRNA, miRNAs are more stable,[88] which
explains their good prognostic behavior in cancer. Over the past
several years, a large number of miRNAs have been reported as
effective indicators for the cancer prognosis.[89–91] It was demonstrated that overexpressed miR-21 was significantly linked
with the poor prognosis and therapeutic outcome of patients
with colon cancer,[89] while downregulated let-7 miRNA was
correlated with poor survival of patients with lung cancer.[91]
In another study, the expression pattern of miR-335 and miR126 were lost when the condition of patients with breast cancer
deteriorated, suggesting their active role in poor metastasis
free survival (i.e., survival till the metastasis is detected).[92]
Apart from miRNAs, few of the recently discovered lncRNAs
also showed fairly good prognostic behavior.[13] For example,
Kogo et al.[90] studied the expression pattern of HOTAIR in 100
tissue samples collected from colon cancer and compared them
with the matched normal sample where substantial changes
in HOTAIR expression was observed. This study was extended
to test samples derived from liver cancer where a strong correlation of upregulated HOTAIR with liver metastasis and
poor disease prognosis were observed. In a similar approach,
Liu et al.[93] detected the overexpression of DANCR lncRNA in
colorectal cancer tissues compared to that of matched normal
tissues and their expression was highly correlated with the histologic grade and lymph node metastasis (Table 1 presents an
overview of diagnostic and prognostic potentials of RNA biomarkers in various cancers).

3.3. Contradictory Findings on Circulating miRNAs as a
Biomarker: Critical Evaluation
Despite recent advances in miRNA biomarker research, circulating miRNAs have not made the translation yet into the clinic,
partly due to their contradictory specificity and inconsistent
reproducibility issues as cancer biomarkers under different
physiological and pathological conditions.[98–104] For example,
Haider et al.[98] reviewed a total of 416 circulating miRNA biomarkers in 57 noncancerous diseases and identified that the
differential expression of the miR-16, -155, -21, -126, and -223
biomarkers were not specific for any particular diseases, rather
associated with at least 10 noncancerous conditions. Witwer
et al.[99] also published an extensive review on circulating
miRNAs and showed the poor specificity and reproducibility of
circulating miRNA as potential cancer biomarkers. In another
study, Leidner et al.[103] reviewed the irregular reproducibility
of breast cancer related miR-21 and miR-155 biomarkers. Egidi
et al.[100] also pointed out the poor specificity issue of circulating
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miRNA. They studied the expression level of miR-21 and miR141 in 38 prostate cancer patients after their radical prostatectomy (i.e., surgical removal of prostate gland) and showed that
serum samples collected from patients with no prostate glands
had significantly elevated level of miRNAs. This finding raised
the concern as to whether elevated levels of miR-21 and miR141 in samples of prostate cancer patients collected after their
radical prostatectomy is indicative of prostate cancer or simply
related to general disease states such as inflammation.
Although, the miRNAs role as a cancer biomarker is under
careful consideration, it is widely accepted that various biological and technical pitfalls associated with miRNA studies,
including lack of automation and standard workflows in laboratories, inefficient sampling and extraction methods, and
platform dependent variations could result in these inconsistencies.[37,101,102,105] One possible solution for avoiding this
variation is to directly screen miRNA that is released from
the tumor rather than screening whole plasma or serum. This
could be achieved by screening the extracellular vesicles (e.g.,
exosomes) derived miRNAs which have the capability of representing parental tumor cells.[99]

4. Detection of RNAs: The Challenges
Despite the recent development of RNA detection methodologies, several major challenges still remain. These challenges
involve the following considerations.

4.1. Stability of RNAs
RNA is generally unstable at room temperature due to the
chance of ribonucleases (RNase) associated degradation. Therefore, both endogenous and exogenous RNases can affect the
accuracy of the detection via progressive degradation of the
target RNA during incubation steps. One potential solution of
this problem is the use of RNase inhibitor in the assay as demonstrated by Frei et al.[106] In their multiplexed quantification
assay for RNAs, referred to as PLAYR (proximity ligation assay
for RNA), RNase inhibitor was used to avoid RNA degradation. This concern is not factual for RNAs available in various
vesicles and biological molecules (e.g., exosomes and apoptotic
bodies). The RNAs in these bodies are usually packaged into
their structures (i.e., exosomal RNAs are protected by the membrane structure of exosome) and thus become inaccessible to
RNases.[63–65]

4.2. Sample Preparation and Choosing the Sample Source
The efficiency of RNA detection is heavily influenced by the type
of sample source and preparation method.[102] Wang et al.[107]
showed that the expression level miRNA can be different in
serum and plasma of the same individual. They found that
miRNA concentrations in serum were higher compared to the
corresponding plasma samples of the same person. They suggested that the presence of platelet-derived miRNAs originating
from the blood coagulation process could be responsible for
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Table 1. RNA biomarkers associated with diagnosis and prognosis of cancer.
Type of RNA

Target

Sample source and type

RNA expression

Lung cancer tissue and serum with healthy
controls

Downregulated

ASAP1 mRNA

10 pairs of epithelial ovarian cancer (EOC) tissue
and normal samples

Upregulated

cyclin D1 mRNA

Tissue samples from 151 patients
with low-grade B-cell lymphoma

Upregulated in 128
patients

Cyclin D1 mRNA as diagnostic marker
of Mantle cell lymphoma (MCL)

[94]

Fusion mRNA

TMPRSS2–ERG
mRNA

Transgenic mice prostate

Upregulated

Diagnostic marker of prostate cancer

[59]

microRNA
(miRNA)

A number of 470
human miRNAs
screened

76 tumor and matched adjacent normal
tissues derived from radical prostatectomy
specimens

10 upregulated and 5
downregulated

miR-96 as prognostic biomarker of prostate
cancer

[95]

Global miRNA- microarray screening

A number of 123 lung cancer
and matched normal tissues

35 upregulated and 3
downregulated

Upregulated miR-21, miR-17-5p, miR-191,
miR-128b, miR-199a-1 as diagnostic biomarkers for lung cancer

[80]

Global miRNA- microarray screening

Tissues derived from 46 colon cancer
and 8 normal individuals

21 upregulated
and 1 downregulated

A number of 8
miRNAs screened

40 prostate cancer tissue with
matched normal tissue samples

2 downregulated

Downregulated miR-205, miR-214 as
diagnostic marker for prostate cancer

[96]

Global miRNA microarray screening

79 breast cancer and 6 normal tissues

15 upregulated and 12
downregulated

Upregulated miR-21, miR-17-5p, miR-29b-2,
miR-146, miR-155, miR-181b-1 as diagnostic
indicator of breast cancer

[80]

Microarray for
screening total 389
miRNAs

197 primary colon tumor and
matched normal tissues

37 miRNAs dysregulated

Upregulated miR-21 linked with the poor survival of patients with colon adenocarcinoma

[89]

DANCR lncRNA

107 colorectal cancer tissues with
paired adjacent normal tissues

upregulated

Upregulated DANCR lncRNA as prognostic
marker for colorectal caner

[93]

HOTAIR lncRNA

100 cancerous and matched
noncancerous tissues collected from patients with
colorectal cancer

upregulated

HOTAIR lncRNA

Serum collected from patients with esophageal
cancer (including 42
tumor resection and 8 without surgery)
and 20 healthy volunteers

upregulated

Messenger
hTERT mRNA, EGFR
RNA (mRNA)
mRNA

Long
noncoding
RNA(lncRNA)

this source-dependent variation. In another report, Leidinger
et al.[108] showed that the influence of ethylenediaminetetraacetic acid (EDTA) on the expression and degradation of
miRNA present in blood samples. EDTA has routinely been
used as an anticoagulant in blood collection tubes for miRNA
analysis in clinical settings. In this method, the sampling tubes
were incubated with EDTA at different time intervals (0 min,
10 min, and 2 h) after the blood draw from 6 healthy individuals. It was observed that with increasing incubation time, the
levels of miRNAs in the blood sample were significantly altered.
The report suggested that transcription and degradation of the
miRNAs in the white blood cells and platelets could still be
dominating inside the sampling tube, causing a noticeable variation in the miRNA level derived from same individual under
two different EDTA-incubation intervals. Therefore, the use
of stabilizing reagents in the blood collection tubes is highly
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Diagnostic and/or prognostic RNA biomarkers Ref.
hTERT mRNA, combined with EGFR mRNA
as both diagnostic and prognostic biomarker
for pulmonary malignancies

[17]

ASAP1 mRNA as prognostic marker of ovarian [93]
cancer

Upregulated miR-21, miR-17-5p, miR-191,
[80]
miR-29b-2, miR-223, miR-128b, miR-24-1,
miR-24-2, miR-155, miR-20a, miR-107, miR-32,
miR-30c, miR-221, and miR-106a as positive
indicators of colon carcinoma

Upregulated HOTAIR as prognostic marker for [90]
colorectal cancer
Upregulated HOTAIR as potential diagnostic
biomarker for esophageal cancer

[97]

recommended to stop unexpected expression and degradation
of miRNA (i.e., variations in miRNA expression level).[102]

4.3. Low Sensitivity due to Ineffective Extraction Methods
The readily available concentration of clinically relevant RNAs
in tissues, serum, or other body fluids is very low. Therefore,
a highly sensitive and specific method needs to be designed
for extracting RNAs from body fluids. The RNA extraction
method is also crucial because a little discrepancy in the analysis could result in false-positive responses. This observation
was also evident from a study by McDonald et al.[109] who demonstrated that the majority of variance in the RNA detection
was derived from the extraction process used. Thus choosing
the right extraction method along with careful optimization
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(i.e., incubation time, centrifuging speed, etc.) of the extraction
steps is necessary for obtaining accurate detection.

differences in gender, race, age, diet of individuals, etc. It has
also been revealed that the variation is more when the sample
size is small (<100 individuals), therefore the variation can be
lessened by recruiting a large cohort of sample.[37]

4.4. Specificity Issues due to the Cross-Talk between RNAs
RNAs originating from the same family often share similar
physicochemical properties and sequences.[110] Consequently,
accurate and sensitive detection of RNAs is often compromised by the background response from the closely related
sequences of nontarget RNAs. Over the past several years,
many approaches have been employed to address this issue.
For example, Castoldi et al.[111] used a special type of thermostable probe known as locked nucleic acid in microarray assay
to specifically detect single base mismatch and closely related
miRNA sequences. In another study, Labib et al.[43] used p19
protein (p19 exclusively binds with double stranded miRNA) in
an electrochemical assay to reduce the background responses
from closely related nontarget sequences.

5. RNA Biomarker Detection Technologies
5.1. Amplification-Based Molecular-Biology Techniques
Amplification-based nucleic acid detection methods such as
RT-qPCR, microarrays, and RNA-seq have been widely used
for RNA biomarker detection and expression analysis. In these
methods, generally the RNA template is reverse transcribed
to complementary DNA (cDNA) using an RT enzyme. RT is a
RNA-dependent DNA polymerase enzyme that creates cDNA
libraries from mRNA. cDNA is then further amplified by PCR
or RNA-seq for detection purpose.[117,118]

5.1.1. RT-qPCR
4.5. Nonspecific Response from Biomolecules
The clinical sample may have complex biological environments
containing various unknown cells and biomolecules such as
proteins, which could nonspecifically be attached on the sensor
surface resulting in false-positive responses. Therefore, a suitable blocking agent such as mercaptohexanol, mercaptoethanol,
poly(ethylene glycol), or bovine serum albumin can be used to
prevent nonspecific bindings.[112]

4.6. Varying Size of RNAs
The length of RNA spans over very small (e.g., miRNA,
18–20 nt) to large (e.g., lncRNA > 200 nt). Compared to longer
RNAs, detection of short RNAs becomes challenging due to
their size match with primers of amplification-based detection
techniques. To address this issue, short RNAs can be enzymatically polyadenylated to produce longer sequences before
the reverse transcription step in RT-qPCR via using oligo-dT
primers.[113] Another possible way to avoid primer match with
target RNA is to use a stem–loop primer during reverse transcription, which formed a nicked RNA hybrid via hybridization
with the 3′ end of the target RNA sequence.[114] On the other
hand, the detection of long RNAs using hybridization-based
approaches also a significantly challenging task. This could be
explained by the fact that, due to the presence of an extra free
oxygen atom in the additional ribose of the RNA structure, long
RNAs are prone to interaction between nucleotides and often
obtain secondary and tertiary structures[115,116] on the sensor
surface, thereby minimizing the hybridization efficiency.

RT-qPCR is a sensitive and widely used method for RNA analysis due to the advantages associated with the requirement of
relatively less starting RNA, wide dynamic range, and better
accuracy.[117] Over the past several decades, a great number of
RT-qPCR-based RNA expression analysis methods have been
developed and also commonly used in clinical trials.[31,32,78,110,119]
In 2005, Chen et al.[114] developed one of the well-known methods
for miRNA analysis, referred to as TaqMan miRNA assay
(Figure 2I). In this method, a unique stem–loop reverse transcriptase was adopted for cDNA conversion which was followed
by TaqMan PCR analysis for the quantification of total 5 miRNAs
present in mouse tissues. This method has since been extensively
used to quantify miRNAs for different applications. The beautiful
feature of this method is that it can differentiate closely related
miRNA sequences having as low as one nucleotide difference.
Mestdagh et al.[120] described a systematic approach to compare
the analytical performance of twelve commercially available
miRNA analysis platforms including RT-qPCR, microarray and
RNA-seq. Among these methods, the RT-qPCR offers the highest
sensitivity for the analysis of miRNA. Although RT-qPCR is sensitive and efficient for measuring relative concentrations of RNA
with respect to an internal standard, it has a limitation for the
absolute quantification of RNAs.[102,120] Another potential weakness of this method is that it usually works with a small number
of expressed genes and, thus, is not suitable for high-throughput
RNA screening.[117] It is also important to note that this method is
effective for already established and prevalidated RNA biomarkers
while microarray and RNA-seq methods are well-suited for the
discovery and validation of novel RNA biomarkers[102,121,122]

5.1.2. Microarray-Based Methods
4.7. Physiological Variation in Humans
Natural variation in the expression levels of RNAs both between
and within individuals is a considerable issue in RNA detection in clinical samples, which mostly could be the result of
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Being a relatively less expensive method, microarray-based
assays can simultaneously profile a large number of RNAs and
offer multiplexed analysis.[33] Typically a microarray comprises
thousands of spots containing multiple oligonucleotides probes
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Figure 2. Amplification-based molecular-biology techniques for RNA biomarker detection. I) A schematic of the TaqMan PCR method for the analysis
of miRNA. Stem–loop RT primers anneal at the 3′ site of the miRNA targets and reverse transcribed to produce cDNA. Then, miRNA-specific forward
and reverse primer and a dye-labeled TaqMan probe are used to quantify the amplified miRNAs. II) A graphical presentation of signal amplification by
the ternary initiation complexes (SATIC) method for isothermal detection of RNAs. In SATIC, an initiation complex comprising target RNA, a circular
DNA template, and a DNA primer is used for rolling circle amplification (RCA). First, the target RNA is hybridized with the complementary sequence of
a circular DNA template. Then, a DNA primer starts the strand elongation by ϕ29 DNA polymerase to perform the rolling circle amplification at 37 °C
for 2 h. The RCA-amplified-DNA products acquire secondary structures (known as Gquadruplex (G4) DNA). These G4s are stained with N3-hydroxyethyl
thioflavin T (ThT-HE) and emit strong fluorescence, allowing the detection of target RNA in real-time. The method was further extended using two
different initiation complexes to enhance the analytical performance. III) A schematic representation of a RNA microarray where the total extracted
RNA acts as a template for reverse transcriptase for production of a cDNA library, which were printed on glass slides followed by probe hybridization,
microarray scanning, and data processing. I) Reproduced with permission.[114] Copyright 2005, Oxford University Press. II) Reproduced with permission.[139] Copyright 2016, American Chemical Society. III) Reproduced with permission.[123] Copyright 2002, Nature Publishing Group.

on a platform, which hybridize with RNAs of interest for largescale expression analysis (Figure 2III).[33,123] A significant
number of microarray-based methods have been developed for
genome-wide analysis of RNAs.[33,34,86,123–125] In 2004, Rogler
et al.[126] developed a reverse format microarray termed an
RNA expression microarray (REM). In REM, total RNAs were
initially reverse transcribed to produce a cDNA library. These
cDNAs were then printed on a solid support of corning gamma
amino propyl (GAP) slides. Humidified hybridization chamber
containing mixed Cy3- and Cy5-labeled probes were designed
to enable simultaneous hybridization of two genes. The applicability of the REM was tested for the specific detection of
albumin, Hnf-4 and Igfbp-1 and c-Myc expression. Zhu et al.[125]
developed another method which detected aberrantly expressed
303 lncRNAs and 565 mRNAs in Helicobacter pylori infected
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cells. Very recently, Hu et al.[127] reported anther microarray
assay to explore the role of miRNAs in gefitinib (a common
EGFR inhibitor available as cancer drug) resistance. By using
the commercial Agilent miRNA-microarrays, they compared
the miRNA expression of a gefitinib-resistant human cell line
with its parental cell line (not resistant to gefitinib). The microarray profile revealed that the expression of miR-149-5p was
altered in the gefitinib resistant cell line. Further RT-qPCR and
biological function tests confirmed the potential involvement of
overexpressed miR-149-5p in gefitinib resistance. The microarray method was also used to detect differential expression of
ZEB1-AS1 lncRNAs in HCC,[128] where ZEB1-AS1 lncRNA was
mostly upregulated in metastatic tumor tissues. Rui et al.[129]
performed a microarray profiling of lncRNAs in lymph node
metastasis of patients with colorectal cancer. They identified
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the dysregulation of a total of 1133 lncRNA transcripts in meta
static lymph node, compared with normal lymph node. In
another microarray study, a total number of 3146 differentially
expressed lncRNAs and 2208 mRNAs in sinonasal squamous
cell carcinoma with respect to noncancerous tissues were identified.[130] These demonstrations suggest that microarrays are
more suitable as discovery tools.[37,121,122]

5.1.3. RNA-seq
The next-generation sequencing of RNAs (RNA-seq, also known
as massively parallel cDNA sequencing) is one of the best alternatives to microarray and RT-qPCR-based methods and has
gained a lot of interest in both small- and large-scale analysis
of RNAs with greater sensitivity and specificity.[4,35,87,118] Apart
from covering a relatively broad range of transcripts, it can also
detect mRNA transcript at a single-nucleotide resolution.[118]
However, as described by Tavallaie et al.,[37] RNA-seq method
cannot always reliably quantify circulating miRNAs in a sample
with highly varying miRNA distribution pattern.

5.1.4. RNA Detection by Isothermal Amplifications
RT-qPCR exponentially amplifies a small amount of target
RNA using multiple heating steps (melting steps) during the
thermal cycling which is not appropriate for the interrogation
of RNA sequences in live cells.[131] To avoid this issue, isothermal nucleic acid amplification strategies, which work at
cellular temperatures could be an alternative choice for RNA
detection. In the past decades, various types of isothermal
amplification-based RNA detection methods have been introduced including reverse transcription loop-mediated amplification (LAMP),[132–134] RNA primed rolling circle amplification
(RPRCA),[135,136] signal mediated amplification of RNA technology,[137] and strand displacement amplification.[138]
RT-LAMP is a one-step isothermal amplification method
that generally provides up to 108-fold amplification of single
target RNA sequence in 1 h using a single tube. It uses a set
of specially designed primers in combination with the mixture
of DNA polymerase and RT.[134] The amplified RNA products
can then be detected by a suitable readout method (e.g., visualization with SYBR Green I stain). Horibe et al.[132] developed
an RT-LAMP-based assay for detecting lymph node metastasis in gastric carcinoma patients. In this method, RNA was
extracted from 92 lymph nodes samples of 9 patients with
gastric cancer followed by the isothermal amplification of
cytokeratin19 (CK19) mRNA. Among 92 lymph nodes samples,
15 were found to be metastasis-positive, which were further
validated with a nested RT-PCR assay. Although the sensitivity
of RT-PCR and RT-LAMP is similar, the analysis time in RTLAMP is much faster. On the contrary, the RPRCA method
uniquely uses RNA primers instead of DNA primers to avoid
the use of reverse transcriptase for detecting small RNAs in a
single tube.[135] In RPRCA, usually the target RNA hybridizes to
its complementary sequence on a circular DNA template, and
is then cleaved by RNase H (30 °C) followed by elongation (via
ϕ29 DNA polymerase at 30 °C), amplification, and detection
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steps.[135,139] In 2016, Fujita et al.[139] developed another RCAbased method referred to as signal amplification by ternary
initiation complexes (SATIC) (Figure 2II). In SATIC, a ternary
initiation complex was formed among the RNA, circular DNA
template, and a DNA primer, followed by RCA at 37 °C. This
caused the amplified products to acquire secondary structures
producing multiple copies of Gquadruplex (G4) DNA. The G4s
were fluorescence-stained with N3-hydroxyethyl thioflavin T
(ThT-HE) for the real-time detection of RNA. The method was
further improved using two different ternary initiation complexes in the RCA process to enable the visual observation.

5.2. RNA Biosensors
Rapid advancements in nanotechnology have led the development of novel biosensor strategies. Typically an effective biosensor is composed of two major components: i) a receptor
(biomolecular recognition species), which specifically recognizes the target analyte, and ii) a transducer (signal-generating
and enhancing element) that recognizes the biomolecular
interaction and converts this interaction into a measurable
signal.[37,140] Over the past several years, several novel biosensors comprising nanopore, optical, and electrochemical readouts have extensively been developed for the quantification and
analysis of RNA biomarkers. Starting with a brief outline of
optical and nanopore-based biosensors, the remaining part of
the review highlights the existing electrochemical sensors.

5.2.1. Optical Sensors
Until now, miRNAs, mRNAs, and rRNAs were reported to be
analyzed and quantified by optical biosensing strategies where
surface plasmon resonance (SPR) and surface enhanced Raman
spectroscopy (SERS) readouts have mostly been employed.[39] In
SPR, surface immobilized molecular interaction between target
RNAs and specific bioreceptor causes a change in the refractive index ,which is measured by the transducer in real-time. It
can also explain the molecular interaction of RNA on sensor via
analyzing binding kinetics.[39] Sipova et al.[141] developed a labelfree and portable SPR sensor to detect miR-122 from mouse
liver tissue. In this method, an additional amplification step
was used where the captured miRNA was subsequently recognized by an antibody to enhance the sensitivity of the assay
(detection limit was 2 × 10−12 m). The assay (35 min) was relatively rapid. More recently, Huertas et al.[142] designed another
SPR sensor for quantifying cancer-specific alternatively spliced
variants of Fas mRNA (Figure 3). This approach is comparable
with RT-qPCR in terms of sensitivity and reproducibility. The
method is also highly specific due to the use of formamide
which significantly reduced the chance of cross hybridization
between variants of Fas mRNA. It also uniquely incorporated a
sample fragmentation step using RNA alkaline hydrolysis prior
the readout to avoid accessibility problems of long mRNA isoforms. The viability of the method was further tested in HeLa
cancer cell lines.
On the other hand, SERS-based methods depend on the
quantification of surface plasmon excitation in metallic
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Figure 3. Real-time and label-free analysis of alternative spliced variants of Fas mRNA by an SPR sensor. Purified total RNA, extracted from HeLa cells,
is passed through two specially designed SPR channels. Each channel is functionalized with one DNA-probe, which is complementary to the splicejunctions of the Fas gene isoforms (either Fas567 or Fas57). Under optimized functionalization and detection conditions, real-time binding of the
targets and the resulting change in the refractive index are monitored. Reproduced with permission.[142] Copyright 2016, Elsevier.

nanostructures of SERS substrates, which has been used
for analyzing different RNA biomarkers including fusion
mRNA.[143–145] Very recently, Wang et al.[143] demonstrated the
application of a “turn-on” SERS method referred to as “inverse
Molecular Sentinel (iMS)” nanoprobes, for multiplexed detection of miRNAs. In this method, the SERS probes used plasmonic-active nanostars as the sensing platform where the
“OFF-to-ON” signal switch relied on the conformational change
of stem–loop (hairpin) capture probes during target hybridization. The clinical applicability of the assay was tested in
breast cancer cell lines using a mixture of the two differently
labeled nanoprobes to detect miR-21 and miR-34a biomarkers
respectively.
In 2007, Seferos et al.[146] introduced a fluorescence method
for mRNA analysis which used a novel intracellular RNA probe
termed as “Nanoflares.” Nanoflares has the unique feature of
transfecting into the live cells for visualizing and quantifying
mRNA. First, 13-nm gold nanoparticles (AuNPs) were functionalized with thiolated oligonucleotides (acting as the recognition element for mRNA transcripts) to develop the nanoflares.
Then, a short reporter sequence tagged with cyanine (Cy5)
dye was hybridized with functionalized AuNPs. This reporter
sequence was considered as “flares” in the nanoflares sensor. In
the absence of target, the Cy5 dye is quenched due to proximity
to the AuNP surface. However, when target RNA is present,
a robust duplex is formed between the RNA and nanoflares
which causes the removal of flare from the AuNP, providing
measurable fluorescence readout. The method was successfully tested in a synthetic target and a real sample for the realtime quantification of mRNA. One obvious disadvantage of the
existing transfecting agents (e.g., lipids and dendrimers) for
RNA analysis is that they can produce toxicity inside the cell.
Furthermore, oligonucleotides-based transfecting agents are
unstable inside the live cells due to their enzymatic degradation, primarily via the action of 3′ exonucleases. This instability
of oligonucleotides inside the live cell and other associated
issues were critically reviewed by Opalinska et al.[147] Nanoflares, on the contrary, are not toxic and are highly stable inside
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the cells. Nanoflares thus have very high potential in detecting
RNAs from live cells and have already been incorporated in several RNA biosensing approaches.[148,149]

5.2.2. Nanopore Sensors
Nanopore sensing tools are one of the most prominent singlemolecule sensors. Typically, in the presence of a conducting
fluid, when a potential is held, nanopores produce electric current due to the charge transport in the holes. The produced
current is highly sensitive to the size and physical properties
of the pore. Thus, detectable current changes can be observed
when the target analyte (e.g., RNA) is trapped inside the pore
after hybridization with a target specific capture probe.[150,151]
Until now, only miRNAs have been interrogated via nanopores.[152–155] Wang et al.[155] developed a unique nanopore
sensor using α-hemolysin protein pore (Figure 4). The method
relied on the translocation of single-stranded oligonucleotides
through the 2 nm sized pore functionalized with a programmable oligonucleotide probe. Both ends of this oligonucleotide
probe were attached with a poly (dC)30 signal tag, which then
became highly specific for target miRNA and thus avoided
their cross-hybridization with nonspecific RNAs. Depending
on the presence of specific miRNA, a measurable signal was
obtained. The method also showed highly sensitive detection
limit of 100 × 10−15 m. Additionally, the sensor was successfully tested to differentiate the relative levels of miR-155 of
healthy and lung cancer patients. A comparative analysis of the
advantages, disadvantages, and analytical functionalities of the
nanopore sensors along with other major RNA detection platforms[39,102,123,152,154,156–161] is summeaized in Table 2.

5.2.3. Electrochemical Biosensors
In recent years, significant progress has been made toward
the development of electrochemical methods to interrogate
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Figure 4. A schematic diagram of lung-cancer-related single-miRNA-molecule (miR-155) capture by a nanopore. a) A microRNA (red) hybridized to a
probe (green) having signal tags on both ends. b) Diagram of current blocks in the nanopore, in the presence of 100 × 10−9 m miR-155 and its capture
probe P155 on the cis side of the pore. The red boxes denote the multilevel current pattern resulting from the hybridization of target miR-155 with the
capture probe. c) A typical multilevel long block of hybridized miR-155 at +100 mV. Right panel: molecular mechanism of hybrid dissociation and
translocation. Level 1: Capture of the target-probe hybrid, unzipping of the target miRNA from the probe followed by the translocation of the probe.
Level 2: Unzipped microRNA staying inside the pore. Level 3: Translocation of the unzipped microRNA through the pore. Lower panel: multilevel current blocks at +150 and +180 mV where the duration of Levels 1 and 3 is decreased with increasing the potential supporting the functionality of the
nanopore model. d) Quantification of miR-155 levels detected by RT-qPCR in trans solutions once the electrical readout is taken. e) A single-level block
(from (b)) generated by a trapped miR-155-probe hybrid (without unzipping and translocation). f) A spike-like short block generated by the translocation of unhybridized miR-155 or probe from the cis solution. Reproduced with permission.[155] Copyright 2011, Nature Publishing Group.
Small Methods 2017, 1, 1700131
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Table 2. Major detection platforms for RNA biomarkers.
Detection platform
or assay

Detection principle

Quantitative reverse
transcription PCR
(RT-qPCR)

Reverse transcription of RNAs to cDNA
followed
by quantitative PCR

Microarray

Advantages

Disadvantages

Amount of RNA
required or
LOD

Established method, sensitive, specific, Expensive, not suitable
Input RNA,
sensitive, ideal for small RNAs, widely for high throughput RNA <ng or ng–μg
available and compatible with laboratory screening and discovery
workflows,
studies, effective only
against established RNAs

Hybridization of RNA with complementary Established method, relatively inexpensive, Relatively lower specificity
probes
high throughput screening, suitable for
and sensitivity, no
prefabricated in the thousands of spots
discovery studies
absolute quantification,
on a microarray platform
cannot efficiently discriminate closely related
miRNAs

References

[102,156,157]

Input RNA,
ng–μg

[102,123,156,157]

RNA sequencing

Preparation of cDNA library from target
RNAs followed by “massively parallel”
sequencing
of library derived cDNA

Can distinguish miRNAs from closely
related RNAs and precursors

Extensive bioinformatics
supports required,
suitable only for relative
quantification

Input RNA,
ng–μg > ng

[102,123,156,157]

Surface Plasmon
resonance
(SPR)

Measurement of refractive index (RI)
changes resulting
from the surface
immobilized molecular interaction between
RNAs and bioreceptor

Real-time and label- free analysis

Low throughput, higher
sample input, longer
assay time

Input RNA,
ng–μg

[39,158]

Nanopore

The charge transport in the nanopore is
halted in the
presence RNA target of interest. The resultant blockade
current is quantified

Sensitive, single molecule sensor

Complicated sensor fabrication, not suitable for
detecting long RNAs

Input RNA,
ng–μg

[152,154]

a) Multistep sensor
fabrications

a) LOD, 0.05 ×
10−15 m

[159]

b) Amplified signal, efficient capture (HP b) Not tested in complex b) LOD, 0.4 ×
probe is thousands fold sensitive than
biological sample
10−15 m
linear capture probe)

[160]

c) Target fusion mRNA is captured on amino c) Simultaneous screening multiple RNA c) Complicated and mul- c) LOD, 1.0 pg
acid/nucleic acid chimeras (ANAs) capture targets, ANA capture probe facilitates low tistep sensor fabrications
μL−1
probe functionalized gold microelectrodes. background response and stable monoVoltammetric readings enable the detection
layer formation on microelectrodes
in the presence of [Ru(NH3)6]3+/[Fe(CN)6]3−
redox probe

[161]

d) Direct adsorption of magnetically capd) Significantly simplified sensor, avoids d) Not suitable for long d) Target fusion
tured target fusion RNAs on the unmodified conventional surface modification and
RNAs
mRNA can be
screen-printed gold electrodes via RNA-gold probe immobilization steps on electrode,
detected from
affinity interaction. Resultant coulombic
relatively inexpensive, highly specific,
minimum 10
repulsion between negatively charged RNA amplification free, noninvasive screening
cancer cells
and ferricyanide ions produce detectable
voltammetric signal.

[41]

Electrochemical
sensors

a) Cisplatin–biotin labeled mRNA/redox a) Amplification free, highly sensitive, low
polymer bilayer on a gold electrode. Enzysample input (5 ng)
matic oxidation of glucose oxidase–avidin
molecules produce detectable amperometric
signal
b) Target mRNA induced conformational
change of hairpin (HP) probe results in a
readable electrochemical signal

clinically relevant RNAs.[37,40,44,161] Most of these methods are
based on the hybridization of target RNA sequences to the surface bound complementary receptor probes (mostly DNA oligonucleotides) on the electrode. The hybridization of RNAs with
probes results in a measurable electrochemical signal. Here,
signal transduction relies on various factors including intrinsic
electroactivity of nucleobases, and the presence of redox indicators (e.g., intercalators such as methylene blue), covalently
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bound redox labels (e.g., nanoparticles), or reporter enzymes
(e.g., phosphatases, peroxidases).[40,162] Then, the detection
of RNAs is mostly read via voltammetric, amperometric, and
impedimetric approaches.[40,163] In parallel to these, few ultrasensitive electrochemical approaches have also been developed
using chip-based nanostructured microelectrodes for multiplexed detection of RNA biomarkers.[161,164,165] In these chipbased sensors, nanostructured electrodes are usually deposited
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on the surface of the chip using photolithography which work
as specific detector for multiplexed analysis.
Electrochemical Biosensing of Coding RNAs: Due to the crucial role of coding RNAs (i.e., mRNA) in disease diagnosis
and prognosis, several novel electrochemical sensors aiming
to detect and analyze mRNA biomarkers have been developed.[40,41,159–161,166–168] One of the earliest mRNA-detection
methods was demonstrated by Xie et al.[159] (Figure 5I). In
this method, first, total extracted RNA was directly labeled
with cisplatin–biotin and allowed to hybridize with a thiolated
oligonucleotide capture probe, which was functionalized on a
gold electrode. Following hybridization of target mRNA on the
electrode surface, glucose oxidase–avidin molecules were introduced in the system which conjugated with biotinylated target
mRNA via the biotin–avidin interaction. Then, the electrode
surface was coated with a cationic redox polymer containing
osmium-bipyridine. Since the target mRNA is attached with
glucose, the current generated from enzymatic oxidation of glucose was directly proportional to the target mRNA concentration in the sample. The viability of this highly sensitive method
was tested for the detection of GAPDH and cancer-specific p53
mRNA (LOD, 0.5 × 10−15 m). Moreover, a partially complementary capture probe (single base mismatch) was introduced in
the sensor, which produced notable drop in the amperometric
response, supporting the excellent specificity of the assay.
The hairpin (HP) DNA probe is one of the most versatile oligonucleotide probes for biomarkers screening and is commonly
being used in optical and electrochemical assays for RNA
detection.[160] The loop area of the hairpin probe is selectively
designed to be complementary to the target RNA sequences.
When RNA is hybridized with the HP probe, the stem loop
structure of the HP opens up allowing the prefunctionalized electroactive reporter molecule to interact, resulting in a
detectable signal. For example, Wei et al.[160] incorporated an
HP probe on a gold electrode in a “signal on” electrochemical
method and successfully detected interleukin (IL)-8 (a potential
noninvasive biomarker for oral cancer) mRNA from saliva. In
this approach, the 3′ end of the HP probe was tagged with a
fluorescein molecule while the 5′biotinylated end was immobilized on the streptavidin modified gold electrode to give the
probe a stem loop structure. In the absence of target mRNA,
resultant steric hindrance inhibits the binding of the anti-fluorescein-HRP conjugate on the electrode surface thereby ceasing
further reaction. When target mRNA is present, the hairpin
opens up and then, in the presence of the TMB substrate, the
bound HRP produces an amplified electrochemical signal. This
signal is directly correlated with the amount of target mRNA
present in the sample. The method was relatively fast and
attained very high sensitively (≈0.4 × 10−15 m). The method was
later extended for the multiplexed detection of mRNA.[167] In a
similar approach, a switchable “on–off–on” technique involving
a stem–loop oligonucleotide probe was used for the detection of
tumor-specific survivin mRNA.[169]
One of the foremost challenges of RNA biomarker detection
in clinical application is to simultaneously screen the very low
amount of readily available RNA biomarkers in complex heterogeneous samples, which could contain many nonspecific targets. These challenges could be addressed via the multiplexed
and highly sensitive analysis of RNAs by employing novel
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nanostructured electrochemical sensors.[161,164,165] For example,
Vasilyeva et al.[161] developed a sensor for the analysis of cancerspecific mRNA fusion using an array of nanostructured gold
microelectrodes. In this method, a novel capture probe, termed
as amino acid/nucleic acid chimeras (ANAs), was immobilized onto the surface of microelectrodes. ANAs significantly
enhance the assay performance compared to the existing
neutral capture-probe-based assay. This is due to the fact that
ANA has relatively good solubility along with the ability of
forming stable monolayer on the sensor. The ANA also specifically can recognize and binds at the junction of gene fusion.
In the presence of [Ru(NH3)6]3+/ [Fe(CN)6]3− redox probe, the
concentration of hybridized mRNA was measured from the voltammetric readout. To illustrate the applicability of the sensor,
chronic myeloid leukemia specific BCR-ABL mRNA fusion was
detected in cancer cell lines. When very high concentration of
the partially complementary capture probe was used along with
the fully complementary BCR-ABL probe, the electrochemical
signal for the complementary targets was unaffected, showing
the high specificity of the assay.
Apart from BCR-ABL, several other fusion mRNAs (e.g.,
TMPRSS2-ERG) have attracted significant interest as cancer
biomarkers due to their role in cancer development and high
specificity (Mertens 2015).[170] Fusion mRNA is transcribed
from fusion gene as the product of chromosomal rearrangements such as translocations, insertions, inversions, and
interstitial deletions where two genes from each side of chromosomal breakpoint may fuse together.[170,171] In addition, the
coding sequences in one gene can be juxtaposed with the regulatory sequences of another gene to form the fusion gene.[170]
Approximately 20% of all types of human cancers are associated with the fusion mRNAs.[172] For example, the TMPRSS2ERG fusion mRNA (originated from mutation between the
TMPRSS2 promoter sequence and the ERG coding sequence)
is uniquely expressed in ≈50% of malignant prostate cancer
cases and considered as one of the finest selective biomarkers
of prostate cancer for their aberrant role in the inhibition of the
apoptosis of prostate gland cells.[59,173]
More recently, Koo et al.[41] have developed an amplificationfree method for detecting prostate cancer specific TMPRSS2:
ERG mRNA fusion (Figure 5II). This method avoids the complicated chemistries underlying the conventional multistep
sensor fabrication steps thereby significantly simplifying the
sensor design. Moreover, the method recruited patients’ urine
samples to extract the TMPRSS2: ERG mRNA for electrochemical interrogation, which offered a significant improvement in
the noninvasive screening of prostate cancer patients. In this
method, first, RNA was extracted and purified from patient
urine samples. TMPRSS2: ERG mRNA transcripts were then
selectively captured by the biotinylated capture probe in the
solution. Next, streptavidin-coated magnetic nanoparticles were
dispersed into the reaction mixture. After magnetic purification, the captured mRNA fusion was directly adsorbed on the
commercially available screen-printed gold electrodes via the
RNA–gold affinity interaction.[174] The adsorbed mRNA (negatively charged) creates higher Coulombic repulsion toward
the negatively charged ferricyanide ions thereby resulting in a
decreased electrochemical signal compared to that of control
and normal sample. The method showed excellent specificity in
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Figure 5. Electrochemical detection of coding RNAs. I) Schematic illustration of an mRNA detection assay using an mRNA/redox polymer bilayer
model: cisplatin–biotin labeled mRNA is hybridized with a thiolated oligonucleotide capture probe functionalized on a gold electrode. Glucose oxidase–avidin molecules are then introduced in the system, which binds the biotinylated target mRNA via a biotin–avidin interaction. Then, the electrode
surface is coated with a cationic redox polymer which mediates the enzymatic oxidation of glucose. As the target mRNA is attached with glucose,
the amperometric current generated from its oxidation is directly proportional to the mRNA concentration in the sample. II) Steps involved in an
amplification-free detection of prostate-cancer-specific TMPRSS2:ERG mRNA using the mRNA–gold affinity interaction: a) TMPRSS2:ERG mRNA is
the fusion between the TMPRSS2 promoter sequence and the ERG coding sequence; b) total RNA is extracted from urine samples followed by specific
capture of TMPRSS2:ERG mRNA via a biotinylated capture probe. The target is then magnetically isolated from the sample pool using streptavidincoated magnetic beads; c) the magnetically captured target mRNA is heat-released and adsorbed on an unmodified screen-printed gold electrode. The
presence of mRNA is analyzed by differential pulse voltammetry in the presence of the [Fe(CN)6]4−/3− redox system. I) Reproduced with permission.[159]
Copyright 2004, American Chemical Society. II) Reproduced with permission.[41] Copyright 2016, American Chemical Society.

detecting TMPRSS2: ERG mRNA while a negative control cell
line (TMPRSS2: ERG fusion gene absent) was used. Until now,
the most preferable approach for identifying cancer associated
fusion transcripts is the next-generation sequencing (NGS),
especially RNA-seq.[171] However, the detection of fusion mRNA
by RNA-seq has been limited by the resultant false-positives
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response.[118,175,176] Moreover, RNA seq for fusion mRNA
heavily relies on the complicated data analysis procedure with
various type of software packages. This was also supported by
a recent study from Kumar et al.[176] who observed substantial
variation in the NGS data analyzed by different fusion-mRNAdetection software tools. In this regard, the amplification-free
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and nonenzymatic electrochemical method has clear advantages over RNA-seq for acquiring relatively accurate detection
of fusion mRNAs.
Electrochemical Biosensing of Regulatory RNAs (Noncoding RNAs): The principle of electrochemical biosensing
of miRNAs is almost the same as that of DNA or mRNA
hybridization biosensors. One example of miRNA detection
strategies is the direct oxidation-based analysis of circulating
miRNA bases.[177] In this method, miR-122 was hybridized
with its inosine substitute capture probe on a carbon-based
nanostructured electrode. Electroactive polymers were also
used on the electrode to increase the electroactive area and
reduce the electrical resistance. Then, direct oxidation of
guanine during RNA hybridization resulted in a measurable
differential pulse voltammetric (DPV) signal. This method
significantly improved the limit of detection of circulating
miRNAs in serum (10 × 10−15 m). The detection limit was
further improved (100 × 10−18 m) in patient serum via the
development of a DNA-concatemer-based ultrasensitive
electrochemical method.[178] In this approach, two auxiliary
probes were self-assembled to form a one-dimensional DNA
concatemers. An HP capture probe was immobilized on the
surface of screen-printed gold electrodes. In the absence
of target miR-21, the HP probe retained its loop structure
offering no binding site for the DNA concatemers. This produced little electrochemical signals. However, when miR-21
was present, the stem–loop structure of the HP capture
probe opened up, allowing their hybridization with DNA
concatemers. Next, the RuHex signal reporter bound to the
negatively charged DNA concatemers on the working electrode significantly amplified the electrochemical signal enabling the detection.
Different intermediates of miRNA biogenesis such as primiRNA, pre-miRNA, and other small noncoding RNAs such
as rRNA share sequence similarities with miRNAs. During
miRNA detection, these nonspecific RNA molecules can interfere with the target miRNA via cross-hybridization resulting
in false-positive response.[179] This issue was addressed via the
incorporation of a special RNA binding protein known as p19
in the sensor.[180] Usually, the p19 protein works as a molecular caliper of small double-stranded RNA (21–23 base pairs)
and isolates miRNAs in a size-dependent and sequence-independent manner. Being more specific, the p19 protein does not
bind to ssRNA, rRNA, mRNA, ssDNA, or dsDNA whereas it
can specifically bind to the double-stranded miRNA.[179] Thus
the inclusion of p19 in the reaction mixture can significantly
reduce the chance of nonspecific detection. Using this exclusive
property of p19 protein, a three-mode electrochemical sensor
was developed for the detection of circulating miRNAs.[43] A
schematic representation of this three-mode sensor is presented in Figure 6. The three-way analysis detects one or multiple miRNAs on gold-nanoparticle-modified screen-printed
carbon electrodes by using square wave voltammetry (SWV) in
the incubation buffer containing K3[Fe(CN)6] and [Ru(NH3)6]
Cl3. In the first modality, the hybridization of the target miR-21
to its complementary thiolated-immobilized probe causes
a modulation of the SWV signal (Figure 6b). A linear range
of detection was found from 1 × 10−15 m to 10 × 10−12 m. In
the second modality, the p19 protein dimer was added to the
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formed hybrid. This amplifies the SWV signal and allows an
ultrasensitive detection of the miR-21 (i.e., linear detection
range to 10 × 10−18 m to 10 × 10−15 m) via binding of the bulky
p19 protein and consequently shielding the electrode surface
(Figure 6c). In the third modalities, a universal displacementbased sensor is formed on the basis of the self-assembled thiolated RNA probe bound to the saturation concentration of
a miRNA, whereas the p19 is attached to the formed hybrid.
Subsequently, a mixture of a new target miRNA (here miR-200)
and its complementary nonthiolated-RNA probe is incubated
with the p19-modified sensor. Because the nonthiolated-RNA
probe is complementary to the miR-200 sequence, a newly
formed hybrid at relatively higher concentration compared to
the concentration of the immobilized hybrid can force the p19
protein to dissociate from the immobilized hybrid on the electrode surface, and to bind to the newly formed hybrid causing
a shiftback of the SWV signal (i.e., the linear detection range
to 100 × 10−12 to 1 × 10−6 m). This displacement-based sensor
can therefore be employed for detection of any type of miRNA
without the need of a thiolated capture probe (Figure 6d).
Moreover, the sensor can distinguish miRNAs with different
A/U and G/C content and differentiate single base mismatch
in miRNAs.
The emerging functional insights of long noncoding RNAs
in gene regulation has triggered extensive studies in the
translational clinical research field.[12,26,51,84] Despite the huge
clinical significance of lncRNAs, their electrochemical detection is not well explored. Until now, only a few reports on
electrochemical biosensing of lncRNAs are available.[181,182]
This could be explained by the fact that lncRNA has a relatively long sequence with a high molecular weight. Moreover,
due to the presence of an extra oxygen atom in RNA sugar,
lncRNAs tend to interact with the nucleic acid backbone via
hydrogen bonding, resulting in secondary or tertiary structures (i.e., hairpin, triplexes, and quadruplexes structures).
Taken together these issues, the commonly used RNA-hybridization-based electrochemical sensors cannot recognize and
effectively capture the target lncRNAs on the electrode surface.
In 2015, Liu et al.[182] used the catalytic amplification ability of
single-wall carbon nanotubes coated with Au–Rh hollow nanospheres (Au/Rh-HNP@SWCNT) to detect nuclear paraspeckle
assembly transcript 1 (NEAT1) lncRNA, which is reportedly
overexpressed in patients with HIV. The nanospheres have the
combined benefits of RNA binding features of gold, unique
electronic properties, and large edge-plane-to-basal-plane
ratio of single-wall carbon nanotubes (SWCNTs), and the surpassing catalytic properties of Rh. In this sensor, the gold (Au)
electrode was first modified with L-cysteine followed by the
formation of a Au monolayer by the electrodeposition of an
L-cysteine-containing gold electrode in a colloidal solution of
Au nanoparticles. The nanomaterial (Au/Rh-HNP@SWCNT
complex) tagged capture probe (RNA fragment containing a
(GGGG) quadruplex) was then allowed to bind with each possible site of AuNPs. To avoid nonspecific binding, the sensor
was soaked with hexanethiol. Finally the sensor was incubated
with hemin solution where quadruplex containing target RNA
binds with hemin resulting in a higher (catalytic) redox signal
of hydrogen peroxides in the presence of HRP, allowing the
quantification of NEAT1.
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Figure 6. Three-mode electrochemical biosensor for multiple miRNA detection: first: a) a thiolated capture probe complementary to the target miR-21
is self-assembled onto a gold-nanoparticle-modified screen-printed carbon electrode; b) the target miR-21 is hybridized with the thiolated probe causing
an enhancement of the square wave voltammetric current (SWV); second: c) the binding of the p19 protein dimer to the formed hybrid attenuates
the SWV signals due to the shielding the electrode surface; and third: d) in the presence of a newly formed hybrid between the target miR-200 and its
nonthiolated complementary probe at high concentration, p19 protein is dissociated from the immobilized hybrid on the electrode surface and to bind
to the newly formed hybrid causing a shiftback of the signal. Electrochemical measurements were performed in the incubation buffer containing 4 ×
10−3 m K3[Fe(CN)6] and 10 × 10−6 m [Ru(NH3)6]Cl3. Reproduced with permission.[43] Copyright 2013, The American Chemical Society.

6. Conclusions
Here, we have provided an overview of the current progress of
RNA-detection technologies with special emphasis on the development of electrochemical biosensors. The major challenges
involved in these strategies along with the diagnostic and prognostic significance of clinically relevant RNAs have also been
discussed. It has been shown that tumor-derived circulating
RNAs can work as a liquid biopsy for the minimally invasive diagnosis of cancer, resulting in less patient discomfort.
Although, their high stability in clinical samples has triggered
huge interest, necessary caution should be taken to ensure the
minimal sample preprocessing of these RNA biomarkers to
retain their high stability.
From the representative examples of different detection technologies, it is apparent that RNA biosensors usually involve
the hybridization of target RNA with a capture probe followed
by a suitable readout method such as electrochemical readout.
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Despite the significant progress made in these electrochemical
methods, still major work needs to be performed to achieve a
biosensor suitable for a point-of-care platform. This is because
most biosensors are merely proof-of-concept demonstrations
and highly dependent on complex sensor fabrications and a
series of optimization steps in a well-equipped laboratory setup. To translate these laboratory-based proof-of-concept demonstrations to clinical applications in real-world settings, there
are many outstanding hurdles. One of the major issues is the
false-positive detection of RNAs due to nonspecific bindings.
To avoid this, an optimized sample extraction protocol and
the development of innovative sensors are urgently required.
Nonetheless, we have seen that several unique methods have
attempted to address these requirements. For example, novel
capture probes such as peptide nucleic acid analogs and microengineered-electrodes-based electrochemical sensors have been
designed to avoid cross-hybridization and increase the hybridization efficiency of RNAs where P19 protein was particularly
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employed to remove nonspecific targets.[43,161] Moreover, a
simplified electrochemical sensor using direct interaction of
target RNA and gold electrode has also been developed to circumvent the multisteps sensor fabrication steps.[41] We have
also observed the recent trends of using novel nanomaterials
to accelerate the signal transduction and obtain amplified and
sensitive detection signal.[182] Despite the rapid advances in
the biosensing of mRNAs and circulating miRNAs, development of electrochemical sensor for lncRNAs detection is still
in its infancy. Considering their huge clinical potentials, more
attention needs to be given to develop an effective and reliable
biosensor for lncRNAs. We believe that the ultimate requirement for transforming the current approaches to point-of-care
platform is the development of fully automated and integrated
biosensors capable of high-throughput screening of RNA biomarkers in a heterogeneous clinical sample. As highly efficient
RNA biosensors have continued to develop, we foresee that an
ideal RNA biosensor with desired clinical applications will be
developed in near future.
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